Collectively, these findings advance the pharmacological landscape of GLP-1 and its derived peptides, suggesting that they are versatile agents for comprehensive treatment strategies for chronic pain syndromes linked with metabolic disorders
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2326 October 2023
The availability of affordable GLP-1 anti-obesity medications, manufactured under FDA regulations, is a significant advancement in addressing one of Mississippis greatest health challenges, said Dr
Daniel Drucker [Biomarker 2023] GLP-1 agonists carry a black box warning for C-cell medullary thyroid cancer, an event that was noted in animal studies, but never in human patients in decades of clinical trials
While semaglutide, the active compound found in many of these drugs, is shown to be effective for short-term weight loss, Ozempic is not currently authorized for use as a weight loss aid